LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung.Yi‐Long Wu, Sarayut Lucien Geater, Wěi Li et al.|Journal of Clinical Oncology|2013Cited by 83
[Combination of docetaxel and cisplatin in the treatment of advanced non-small cell lung cancer].Hao Liu, Xi Yan, Meng Qiu et al.|PubMed|2002Cited by 0
[STE029 Overcomes EGFR-TKI Resistance in Human Lung Adenocarcinoma].Lin Huang, Qinghua Zhou, Mei Hou et al.|PubMed|2022Cited by 0